Education
About Us
Working with TipRanks
Follow Us
Alpha Tau Medical Ltd (DRTS)
:DRTS
DRTS Stock Chart & Stats
$3.94
$0.35(10.45%)
At close: 4:00 PM EST
$3.94
$0.35(10.45%)
Day’s Range― - ―
52-Week Range$2.30 - $4.69
Previous CloseN/A
Volume116.73K
Average Volume (3M)59.17K
Market Cap
$327.79M
Enterprise Value$322.16M
Total Cash (Recent Filing)$72.21M
Total Debt (Recent Filing)$13.50M
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Mar 05, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding84,699,720
10 Day Avg. Volume47,760
30 Day Avg. Volume59,172
Financial Highlights & Ratios
PEG Ratio-0.96
Price to Book (P/B)3.46
Price to Sales (P/S)0.00
P/FCF Ratio-9.84
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-9.38
Forecast
1Y Price Target
$7.00Price Target Upside77.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.51
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe company has started patient treatment in its U.S. pilot study of Alpha DaRT in patients with pancreatic cancer.
Regulatory ApprovalsAlpha Tau has secured a radioactive material license from New Hampshire Bureau of Public Health Protection, Radiological Health Section.
Unmet Medical NeedsAlpha DaRT has the potential to address the highly unmet need in oncology for pancreatic cancer, which has approximately 66,000 new cases in the U.S. annually with a 13% 5-year survival rate.
Bears Say
Alpha Tau Medical Ltd News
DRTS FAQ
What was Alpha Tau Medical Ltd’s price range in the past 12 months?
Alpha Tau Medical Ltd lowest stock price was $2.30 and its highest was $4.69 in the past 12 months.
What is Alpha Tau Medical Ltd’s market cap?
Alpha Tau Medical Ltd’s market cap is $327.79M.
When is Alpha Tau Medical Ltd’s upcoming earnings report date?
Alpha Tau Medical Ltd’s upcoming earnings report date is Mar 05, 2026 which is in 91 days.
How were Alpha Tau Medical Ltd’s earnings last quarter?
Alpha Tau Medical Ltd released its earnings results on Nov 20, 2025. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.111 by -$0.039.
Is Alpha Tau Medical Ltd overvalued?
According to Wall Street analysts Alpha Tau Medical Ltd’s price is currently Undervalued.
Does Alpha Tau Medical Ltd pay dividends?
Alpha Tau Medical Ltd does not currently pay dividends.
What is Alpha Tau Medical Ltd’s EPS estimate?
Alpha Tau Medical Ltd’s EPS estimate is -0.12.
How many shares outstanding does Alpha Tau Medical Ltd have?
Alpha Tau Medical Ltd has 84,699,720 shares outstanding.
What happened to Alpha Tau Medical Ltd’s price movement after its last earnings report?
Alpha Tau Medical Ltd reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.111. Following the earnings report the stock price went up 10.086%.
Which hedge fund is a major shareholder of Alpha Tau Medical Ltd?
Currently, no hedge funds are holding shares in DRTS
Alpha Tau Medical Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (77.66% Upside)
$7.00 (77.66% Upside)
Blogger Sentiment
Bullish
DRTS Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.90%
12-Months-Change
Fundamentals
Return on Equity
-54.38%
Trailing 12-Months
Asset Growth
15.39%
Trailing 12-Months
Company Description
Alpha Tau Medical Ltd
Alpha Tau Medical Ltd (DRTS) is a medical technology company focused on the research, development, and commercialization of innovative cancer treatment solutions. The company specializes in the development of Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), a breakthrough approach to cancer therapy that harnesses the power of alpha-emitting isotopes to selectively destroy cancerous tumors while minimizing damage to surrounding healthy tissue. Alpha Tau Medical operates within the biotechnology and healthcare sectors, striving to advance cancer treatment options and improve patient outcomes.
DRTS Stock 12 Month Forecast
Average Price Target
$7.00
▲(77.66% Upside)
Technical Analysis
Larimar Therapeutics
―
Capricor Therapeutics
―
Benitec Biopharma
―
Aura Biosciences Inc
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
―
Insiders
0.04% Mutual Funds
0.65% Other Institutional Investors
99.30% Public Companies and
Individual Investors